Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?
The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...
Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies
President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...
Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics
The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...
Make US Pharma Great Again!? – Part 2
Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...
Make US Pharma Great Again!? – Part 1
The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...
Econometric Analysis Of Biopharmaceutical Transfer Pricing
The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...
Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?
The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...
Patient Claims Versus EHR Data – How To Choose Between The Two?
The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...
Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?
The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...
As the coronavirus (COVID-19) global pandemic unfolds, we would like to share our plans to conduct our business seamlessly while giving utmost priority to the health and well-being of our employees and our ecosystem of customers, vendors, and partners.
Our hearts go out to anyone directly or indirectly impacted by this pandemic. We are inspired by the selfless service of healthcare workers, first responders, and other professionals who continue to serve the people in need.
Our two main priorities at Axtria include:
We pride ourselves on being a highly customer-centric company. Rest assured, we will continue to help achieve all business goals by ensuring that our team is fully equipped to stand in support. Our integrated cloud platforms enable global commercial organizations to work seamlessly and automate manual processes. They are built from the ground up to support teams that need to work remotely.
To ensure health and safety, we have asked our employees globally to follow the guidelines of the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and maintain social distancing, work from home, and swap in-person meetings with phone and video calls. Assuredly, our employees are well-versed in remote work, given our technology infrastructure, ongoing training, and existing processes. We have also rescheduled all in-person events in the coming weeks to digital platforms. Doing so allows us to suspend all unnecessary business travel and large gatherings.
Lastly, we will continue monitoring the COVID-19 data and will make operational adjustments as needed. As a data analytics company, we are committed to making data-driven decisions in every aspect of the business. We shall continue doing so using the most reliable data - from the WHO, the CDC, data-based case tracking via Johns Hopkins University (JHU), as well as through national and local administrations.
As always, Axtria will continue to provide our unwavering support. In dealing with the present circumstances, we will continue employing every effort to deliver uninterrupted services.
Further, you can bank on us to alert you of any protocol changes while encouraging you to approach us with your feedback and queries – not just as business partners, but as valued friends.
On behalf of all Axtrians, I wish you and your families safety and good health during these trying times.
We are isolated but united!
All the best,